Sensovation Acquired by Miltenyi Biotec GmbH

    We are proud to be part of the Miltenyi-Biotec success story. Sensovation is looking forward to provide even better support to our existing customers, as well as to innovative new products for biotech and diagnostics.

    Press Release

     

    Miltenyi Biotec GmbH

    Miltenyi Biotec acquires Sensovation

     

    Bergisch Gladbach / Radolfzell, June 1, 2017 - Miltenyi Biotec, a global pioneer in cell processing and the development of technologies for cell therapy, has acquired Sensovation AG based in Radolfzell, which specializes in the development and production of imaging systems for clinical diagnostics and biotechnology, from the existing shareholders HeidelbergCapital and KfW / tbg.

    Founded in 2000, Sensovation AG has established itself as a specialized provider of systems for digital pathology and multiplex diagnostics. At the Radolfzell site, the company employs nearly 30 highly qualified specialists in the areas of optics, mechanics, electronics and informatics. With the acquisition, Miltenyi Biotec is extending its own product portfolio and is planning to further expand the location in Radolfzell and to apply the special know-how of the employees for the development of new products. Stefan Miltenyi, Founder and CEO of Miltenyi Biotec: "We are very much looking forward to working with the new colleagues in Radolfzell, whose expertise in the development and serial production of high-precision devices in the diagnostics field has convinced us."

    Paul Hing, founder and CEO of Sensovation, commented: "With this acquisition, Sensovation and its employees are opening up a wide range of new possibilities for product development by linking the many years of experience in the field of device development and production with the medical and diagnostic content of Miltenyi Biotec.

    Dechert LLP, Munich with Christian Böhme, Senior Associate (lead manager), Julia Braun, Senior Associate, Clara Gollwitzer, Associate and Berthold Hummel, Partner, supervised the transaction on behalf of the seller consortium; SGP Rechtsanwälte, Munich with Dr. Andreas Schrettl (lead manager) and Dr. Johannes Richter represented the Miltenyi Biotec Group as the purchaser.

     

    Sensovation AG

    Sensovation develops and manufactures intelligent imaging systems that are used primarily in clinical diagnostics and biotechnology. These imaging systems range from highly sensitive scientific cameras to devices for multiplex diagnostics to innovative digital microscopy systems for pathology. Sensovation is primarily active in the OEM business. The OEM partners use the Sensovation products for detection and data analysis in their globally marketed diagnostic systems.

     

    Miltenyi Biotec

    Miltenyi Biotec develops products and services that advance biomedical research and cell therapy. The extensive MACS® product portfolio allows scientists and clinical users to isolate, analyze, process and apply primary cells and related derived cells. The integrated technologies include a variety of applications for sample preparation, cell isolation, cell sorting, flow cytometry, cell culture, and molecular analysis. More than 2,000 employees in 25 countries are passionately developing solutions that contribute to scientific progress and promote the development of cellular therapies.